- Identification of patients with EGFR exon 20 insertion–positive NSCLC
- Overview of the latest clinical data on new and emerging agents targeting EGFR exon 20 insertions
- Understanding the biology and pathology of the toxicity profile associated with agents targeting EGFR
- Monitoring and management strategies for AEs associated with newer EGFR-targeted agents
Date / Time
Marianne Davies, DNP, CNS, ACNP-BC, AOCNP
Adult Specialty Program
Yale University School of Nursing
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut
Matthew Gubens, MD, MS
Medical Director, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California
The goal of this activity is to improve the knowledge, confidence, and competence of oncology nurses, nurse practitioners, and clinical nurse specialists to understand and explain clinical data on recently approved therapies targeting EGFR exon 20 insertion mutations and the differences in monitoring and managing AEs for their patients with lung cancer receiving these therapies.
This educational program is intended for oncology nurses, nurse practitioners, and clinical nurse specialists who care for patients with lung cancer.
Upon completion of this activity, participants should be able to:
- Discuss the significance of EGFR exon 20 insertions with appropriate patients with lung cancer
- Evaluate the clinical data of new and emerging agents targeting EGFR exon 20 insertion mutations
- Describe the biology and pathology of the EGFR-targeting toxicity profile
- Develop care plans for monitoring and managing agent-specific adverse events for the treatment of patients with EGFR exon 20 insertion NSCLC receiving these new therapies
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.